Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial

作者：Nourhan El Ahmar, Morgan A. Paul, Berkay Şímșek, Sayed Matar, Opeyemi A. Jegede, Yasmin Nabil Laimon, Varunika Savla, Razan Mohanna, Gabriel Roberti De Oliveira, Aseman Sheshdeh Bagheri, Thomas Denize, Destiny J. West, Maxwell D. Seager, Maxine Sun, Toni K. Choueiri, Wanling Xie, Gordon James Freeman, Arlene H. Sharpe, David A. Braun, Naomi Balzer Haas, Hans J. Hammers, Mehmet Asım Bilen, Mark N. Stein, Jeffrey Alan Sosman, Catherine J. Wu, David F. McDermott, Michael B. Atkins, Sabina Signoretti · 年份：2026 · DOI：10.1158/1078-0432.33253038 · 研究领域：Medicine、Oncology、Internal medicine、Cancer research

Supplementary Table 9. ORR and PFS per density of CD8+PD-1+TIM3-LAG3- TILs (high vs low) combined with density of CD163+ TAMs (high vs low).